Study to Evaluate Iovera®° in Adult Patients Undergoing Total Knee Arthroplasty

Stopped early · Not applicable · Has a placebo group

Conditions studied: Post-Operative Pain Management

In brief

Primary objective: The primary objective of this study is to evaluate postsurgical pain control, after presurgical iovera° treatment plus EXPAREL® and standardized multimodal therapy compared with presurgical sham iovera° treatment plus EXPAREL and standardized multimodal therapy in subjects undergoing primary unilateral total knee arthroplasty (TKA). Secondary objectives: The secondary objectives of this study are to compare postsurgical pain control or postsurgical total opioid consumption, opioid-free status, physical function, sleep quality, and safety of presurgical iovera° treatment plus EXPAREL and standardized multimodal therapy with presurgical sham iovera° treatment plus EXPAREL and standardized multimodal therapy, in subjects undergoing primary unilateral TKA

Key facts

Study ID

NCT04191031

Run by

Pacira Pharmaceuticals, Inc

People needed

79

Starts

2020-09-30

Expected to finish

2022-07-12

Last updated by the study team

2023-01-25

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, at least 22 years of age at screening.
• Scheduled to undergo primary, unilateral, tricompartmental TKA under spinal anesthesia.
• Primary indication for TKA is degenerative osteoarthritis of the knee.
• American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.
• Anticipation of discharge to home after inpatient acute postsurgical phase based on age, comorbidities, home environment, social support, and the judgment of the Investigator.
• Females of childbearing potential must have a negative pregnancy test result prior to enrollment and agree to use a highly effective method of birth control during the study. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year). Post-menopausal or surgically sterile females would not require a pregnancy test.
• Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.

You may not qualify if…

• History of prior contralateral TKA within 6 months or open knee surgery on the knee being considered for TKA. Prior arthroscopy is permitted.
• Planned concurrent surgical procedure (e.g., bilateral TKA) or planned additional surgery within 90 days of study surgery.
• Undergoing unicompartmental TKA or revision TKA.
• Concurrent painful physical condition that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the knee surgery and which may confound the postsurgical assessments (e.g., significant pain from other joints including the non-index knee joint, chronic neuropathic pain, concurrent or prior contralateral TKA, concurrent foot surgery).
• Comorbidity that, in the judgment of the Investigator, may affect the subject's ability to participate in the study and postsurgical rehabilitation.
• Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications (i.e., bupivacaine, lidocaine, acetaminophen, tranexamic acid, celecoxib, naproxen, meloxicam).
• Use of any of the following medications within the times specified before TKA: long-acting and short-acting opioid medications within 6 weeks; or NSAIDs (except for low-dose aspirin used for cardioprotection) within 3 days or 5 elimination half-lives, whichever is longer.
• Initiation of treatment with any of the following medications within 1 month prior to the screening visit or ongoing concomitant use if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, he or she must be on a stable dose for at least 1 month prior to screening visit.
• Current use of systemic glucocorticosteroids within 1 month prior to screening in this study, intra-articular corticosteroid injections within 6 weeks, or Zilretta within 3 months.
• History of coronary or vascular stent placed within the past 6 months (may be extended to 1 year if medically indicated per physician discretion).
• Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past 6 months (may be extended to 1 year if medically indicated per physician discretion).
• Any clotting disorder and/or use of an anticoagulant (e.g. warfarin, clopidogrel, etc.) within seven (7) days prior to administration of ioveraº treatment.
• Rheumatoid or inflammatory arthritis.
• History of severely impaired renal or hepatic function (in the judgment of the investigator).
• Any neurologic or psychiatric disorder that might affect postsurgical pain or interfere with study assessments.
• Malignancy in the last 2 years, per physician discretion.
• History of misuse, abuse, or dependence on opioid analgesics, other prescription drugs, illicit drugs, or alcohol within the past 2 years.
• Use of marijuana, including medical use, within 6 weeks prior to screening visit or continuation thereafter.
• Body weight <50 kg (110 pounds) or a body mass index >40 kg/m2.
• Previous iovera° treatment.
• Greater than 15° malalignment (varus or valgus) on presurgical radiograph.
• Prior surgery in the treatment areas that may have altered the anatomy of nerves intended to be treated with the ioveraº system or result in scar tissue in the treatment area.
• Open and/or infected wounds at or near the treatment site.
• Any other local skin condition at the treatment sites that in the Investigator's judgment would adversely affect treatment or outcomes.
• History of cryoglobulinemia.

Where it is running

• Sah Orthopaedic Associates at the Institute for Joint Restoration — Fremont, California, United States
• Lotus Clinical Research — Pasadena, California, United States
• Phoenix Clinical Research — Tamarac, Florida, United States
• Towson Orthopaedic Associates — Towson, Maryland, United States
• Northwell Health — New York, New York, United States
• First Surgical Hospital — Bellaire, Texas, United States
• Legent Orthopedic Hospital — Carrollton, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.